Company Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics.
The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing.
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.
The company was incorporated in 2012 and is headquartered in San Jose, California.
| Country | United States |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Talat Imran |
Contact Details
Address: 2051 Ringwood Avenue San Jose, California United States | |
| Website | https://www.ranitherapeutics.com |
Stock Details
| Ticker Symbol | RANI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001856725 |
| CUSIP Number | 753018100 |
| ISIN Number | US7530181004 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Talat Imran | Chief Executive Officer & Director |
| Svai S. Sanford | Chief Financial Officer |
| Alireza Javadi | Vice President of Technical Operations |
| Arvinder Dhalla | Vice President of Clinical Development |
| Bella Vazquez | Vice President of Human Resources |
| Dr. Mir Hashim | Chief Scientific Officer |
| Kate McKinley M.B.A. | Chief Business Officer |
| Mir A. Imran | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13D/A | [Amend] Filing |
| Oct 17, 2024 | 4 | Filing |
| Oct 16, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 424B5 | Filing |
| Sep 11, 2024 | 8-K | Current Report |
| Aug 06, 2024 | 10-Q | Quarterly Report |